Accelerate biotechnology

Article: SIDUS® technology enables first clinical study with live attenuated Zika vaccine

Batavia Biosciences has, with its know-how developed under the SIDUS® technology, extensive expertise in house for the production and testing of viral vector based products, like lentiviral vectors, adenoviral vectors, AAV vectors and Measles vectors. This knowledge covers a broad area; from virus DNA construction and modification, to making research batches and clinical batches, including the development of vector specific assays. A combination of Themis’ vaccine manufacturing process and Batavia Biosciences’ knowledge and experience from its SIDUS® technology made it possible for Themis to rapidly receive clinical material. This way they were one of the first companies worldwide to test a candidate Zika vaccine for safety and efficacy in humans.

Full article (in Dutch)

SIDUS® technology

Virus & Viral vector generation

Clinical Manufacturing